To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), an American biotechnology company, on Monday announced that it planned to acquire 23andMe Holding Co.'s Personal Genome Service, Total Health ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron intends for 23andMe to continue its consumer genome services without interruption. The transaction, pending ...

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

This includes the company’s Personal Genome Service (PGS) and Total Health and Research Services business lines, but not the Lemonaid Health subsidiary. Lemonaid Health, a telehealth company ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...